Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 463 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-risk Myeloid Malignancy Clear all

Conditions: Acute Myeloid Leukemia
Interventions: Fludarabine, Melphalan, Pembrolizumab; Drug
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years to 78 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions: 5-azacytidine (5-aza) maintenance therapy after transplant; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse Leukemia, MDS (Myelodysplastic Syndrome), Relapsed Non-Hodgkin Lymphoma, Acquired Aplastic Anemia, Inherited BMF Syndrome, Immunodeficiency, Primary Immune Regulatory Disorder, Hemoglobinopathies, Bone Marrow Failure, Inborn Errors of Metabolism, HLH
Interventions: Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3, Phase 2 Maximum Tolerated Dose determined in Phase 1, Phase 2 Established Dose from prior study, NCT03810196; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 25 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Blasts Under 10 Percent of Bone Marrow Nucleated Cells, Therapy-Related Myeloid Neoplasm
Interventions: Laboratory Biomarker Analysis, Nivolumab; Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Interventions: Navitoclax, Venetoclax, Decitabine; Drug
Lead sponsor: Jacqueline Garcia, MD; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Acute Myelogenous Leukemia
Interventions: Decitabine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Leukemia
Interventions: 5-azacitidine, Allogeneic Hematopoietic Cell Transplantation (HCT); Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 68 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine; Procedure · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: beclomethasone dipropionate; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 5 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Relapsed Adult Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
Interventions: DREAMLAND, VITAL WELLNESS; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Boston, Massachusetts • Durham, North Carolina • Seattle, Washington

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia
Interventions: GTI-2040, cytarabine, pharmacological study, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions: Cytarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Prexasertib; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: aldesleukin, recombinant interferon alfa, sargramostim, busulfan, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 2
States / cities: Denver, Colorado • Seattle, Washington

Conditions: Myelodysplastic Syndrome, Acute Myelogenous Leukemia
Interventions: 5-Azacytidine (5-aza), Valproic Acid, All-Trans Retinoic Acid (ATRA); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 3 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: BP1001 (varying dose), BP1001 (fixed dose), Dasatinib; Drug
Lead sponsor: Bio-Path Holdings, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain (Nervous System) Cancers
Interventions: Disulfiram (DSF); Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Leukemia
Interventions: Filgrastim, Busulfan, Cyclophosphamide, Cyclosporine, Decitabine (DAC), Methotrexate, Methylprednisolone, Tacrolimus, Allogeneic Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation; Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Venetoclax, Decitabine, Fludarabine, Busulfan, Total Body Irradiation; Drug · Radiation
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions: PF-04449913 (Glasdegib), Azacitidine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 9 more

Conditions: Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Interventions: SGR-2921; Drug
Lead sponsor: Schrödinger, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: Denver, Colorado • Fairway, Kansas • Buffalo, New York + 9 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Mylotarg, Cytarabine; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Syndrome, Rhabdomyosarcoma, Ewing Sarcoma, Primitive Neuroectodermal Tumor, Osteosarcoma, Neuroblastoma
Interventions: TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate; Procedure · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 7 Months to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions: Azacitidine, SL-401, Venetoclax; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 3
States / cities: Duarte, California • Boston, Massachusetts • Houston, Texas

Conditions: Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
Interventions: sunitinib malate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

Nivolumab in AML in Remission at High Risk for Relapse

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Novel Digital Application for Patients With Acute Leukemia

GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia

Phase II 5-Azacytidine Plus VPA Plus ATRA

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia